The lozenge of black mulberry leaf extract possesses activity as a α-glucosidase inhibitor. - GreenMedInfo Summary
The formulation of lozenge using black mulberries (L.) leaf extract as anα-glucosidase inhibitor.
J Pharm Bioallied Sci. 2020 Apr-Jun;12(2):171-176. Epub 2020 Apr 10. PMID: 32742116
Background: Diabetes mellitus is a chronic metabolic disease, which possibly leads to kidney, brain, heart failure, and other organ complications, subsequently harming human health. These symptoms have been prevented using the leaf of black mulberry (BM), as a traditional medicine, because the phenolic compounds contained are able to decrease blood glucose concentration. Meanwhile, previous reports have shown that BM contains 1-deoxynojirimycin, with strong activity as anα-glucosidase inhibitor. The aim of this study, therefore, was to formulate and evaluate BM leaf extract in lozenge dosage form as an α-glucosidase inhibitor.
Materials and Methods: The leaves of BM were extracted using the maceration method, where ethanol (70%) served as a solvent, and the inhibitory activity of the sourcedα-glucosidase enzyme was determined throughstudy. Subsequently, the extract was formulated into lozenge dosage form and evaluated for physical stability and also the effect ofα-glucosidase enzyme.
Results: The result showed an inhibitory activity of BM leaf extract against the enzymeα-glucosidase, with a half maximal inhibitory concentration (IC) value of 357.6μg/mL, whereas the lozenge formulation containing 43% of extract as well as 5% polyvinylpyrrolidone showed the best physical stability as compared to other formulas. However, the lozenge inhibits α-glucosidase enzyme with an ICvalue of 549.7μg/mL.
Conclusion: It was established that the lozenge of BM leaf extract possesses activity as anα-glucosidase inhibitor.